JP Morgan Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Biomarin Pharmaceutical and raises the price target from $111 to $120.
September 05, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has increased its price target for Biomarin Pharmaceutical from $111 to $120 while maintaining an Overweight rating, indicating confidence in the company's future performance.
The increase in price target from $111 to $120 by JP Morgan, along with maintaining an Overweight rating, suggests a positive outlook for Biomarin Pharmaceutical. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100